Prochlorperazine is a potent phenothiazine antipsychotic, derivative of the piperazine group, now largely used as an antiemetic and to treat vertigo. The effects of this drug is apparent at all levels of the nervous system. It antagonizes postsynaptic dopamine D1 receptor that activates adenylate cyclase and synthesis of cAMP. It also antagonizes D2 receptors which do not activate adenylate cyclase. It also inhinits pre- and post synaptic adrenoreceptors and also acetylcholine, serotonin and histamine receptors. These various pharacodynamic actions combine to produce not only antipsychotic, but also central antiemetic and sedative effects.
Prochlorperazine Maleate or Mesilate
(in Tablet form)
Prophylaxis of nausea and vomitting: As maleate or mesilate: 5-10 mg bid/tid. May also be given rectally.
Vertigo: As maleate or mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid.
Adjunct in severe anxiety disorders: As maleate or mesilate: 5-10 mg, up to 3-4 times daily.
Nausea and vomiting: As maleate or mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid.
Psychoses: As maleate or mesilate: 12.5 mg bid for 7 days, adjusted gradually to 75-100 mg daily according to response. Usual maintenance dose: 25-50 mg daily.
Oral (Child) –
1-5 yr: 1.25-2.5 mg, May be given up to tid, if necessary;
5-12 yr: 2.5-5 mg, May be given up to tid, if necessary.
Manufacturer: Square Pharmaceutical Ltd.